Drugs and FDA
FDA approves Infilbray for neurological symptoms of type 3 Gaucher disease
Infilbray is the first FDA-approved treatment for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg.

The FDA approved Sanofi’s Infilbray tablets, also known as venglustat, as the first treatment for neurological symptoms of type 3 Gaucher disease. The drug is approved for adults and pediatric patients weighing at least 15 kg.
The FDA said approval was based on a study of 43 patients aged 12 years and older who had achieved systemic disease stabilization with enzyme replacement therapy. Patients received Infilbray once daily or intravenous enzyme replacement therapy every two weeks for 52 weeks. The FDA said patients taking Infilbray improved on a measure combining assessments of ataxia and cognitive function. MedPage Today reported significant improvements related to those symptoms (P=0.0137). The FDA said reported side effects include gastrointestinal symptoms and mood effects. Prescribing information warns of suicidal thoughts and behavior, potential lens clouding in pediatric patients, and possible harm to fetal development during pregnancy.


